The products of the Bosnian pharmaceutical giant are in Turkey with the assurance of Abdi İbrahim

Abdi İbrahim, the leader of the Turkish pharmaceutical industry, signed a cooperation agreement with Bosnia and Herzegovina’s largest pharmaceutical company, Bosnalijek. From now on, Abdi İbrahim will undertake the sales of Bosnialijek’s respiratory medicine and food supplements based on lysozyme, an enzyme effective in the natural immune mechanism of our body, in the Turkish market.

Turkey’s healing power, Abdi İbrahim, has cooperated with the Bosnian pharmaceutical company of Bosnalijek and announced that the respiratory medicine and lysozyme-based food supplements of Bosnalijek will be brought to Turkey with the assurance of Abdi İbrahim.

The cooperation became official at the meeting held in Sarajevo by CEO Süha Taşpolatoğlu, International Markets Group President Köksal Ülgen, and Business Development Director Sevgi Özalp from Abdi İbrahim’s top management with the senior executives of Bosnalijek.

“We continue to bring health products to our consumers”

Süha Taşpolatoğlu, CEO of Abdi İbrahim, which has been the uninterrupted leader of the Turkish pharmaceutical industry for 21 years, stated that they are pleased to work with Bosnalijek, who shares their passion for improving human health. Taşpolatoğlu: “We are happy to introduce innovative health products, which have been scientifically proven to contribute to human health, to the consumers in our country. Turkey and Bosnia and Herzegovina are two friendly countries with close political and economic relations. Our teams felt a strong bond from the very first meeting, and this bond turned into an important collaboration. We will continue to bring consumer health products scientifically proven to improve and protect human health to Turkey and to bring them to our consumers.

“We aim to achieve a high market share”

Bosnialijek General Manager Nedim Uzunović stated that one of the most important strategic goals of Bosnalijek is to enter the Turkish market and to offer its unique lysozyme-based products to the Turkish people. Uzunović continued his words as follows; “Turkey is among the 20 largest pharmaceutical markets in the world and is one of the attractive markets for international companies. We are proud and happy that our inhalation medicine and lysozyme-based food supplements have entered the Turkish market. Turkey is the world’s largest and competitive market for sore throat medicines. Nevertheless, we believe that we will be the leader in this product segment by gaining a high market share because we will work with Abdi İbrahim, Turkey’s largest pharmaceutical company and market leader. We are very proud that Abdi İbrahim agreed to cooperate with Bosnalijek. We hope that this partnership will develop further in the future and continue in other markets.”

About Abdi İbrahim:

The foundations of Abdi İbrahim, the leader of the Turkish pharmaceutical industry, were laid in 1912 in a small pharmacy in Istanbul’s Küçükmustafapaşa district by Pharmacist Abdi Nadir İbrahim Bey, who started his journey of improvement. Abdi İbrahim, which develops its own products in addition to working with 30 licensors, has the widest product portfolio in the industry with nearly 250 brands and more than 500 products. With its strong vision, dynamic structure and contemporary appearance, Abdi İbrahim has been leading the Turkish pharmaceutical industry since 2002. Abdi İbrahim, which operates in 16 countries outside of Turkey with its own organizational structure, exports to more than 70 countries, from European Union countries to Canada, from North Africa to Asia, and creates the highest employment in the Turkish pharmaceutical industry with its 5,500 qualified employees. Abdi İbrahim’s R&D Center, chemical products production facility, Turkey’s largest biotechnological drug production facility, AbdiBio, Hormone Production Facility, Sterile Ophthalmology & Sterile Inhalation Production Facility, and Sterile Injection & Inhalation Production Facility, which will start production in 2023, in Abdi İbrahim’s production complex in Istanbul Esenyurt. Oncology Production Facility is located. It also has R&D Centers and production facilities in Kazakhstan and Algeria.

About Bosnialijek:

Established in 1951, Bosnalijek is the largest pharmaceutical manufacturer in Bosnia and Herzegovina. Every year, Bosnalijek expands its product range with new treatment solutions suitable for customer needs; focuses on the digestive system and metabolism, cardiovascular system, systemic infections, skin, musculoskeletal, nervous and respiratory systems, and the effects of systemic hormonal drugs with peroral, parenteral and topical administration. Bosnialijek’s product portfolio also includes dietary supplements and disinfectants.